Barclays’s ACELYRIN SLRN Stock Holding History

Barclays’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-82,871	Closed	-$205K	–	5518
2025 Q1	$205K	Sell	82,871 -33,773	-29%	-$80.3K	﹤0.01%	4016
2024 Q4	$366K	Buy	116,644 +20,236	+21%	+$98K	﹤0.01%	4009
2024 Q3	$475K	Buy	96,408 +65,188	+209%	+$337K	﹤0.01%	3810
2024 Q2	$138K	Sell	31,220 -761,950	-96%	-$3.57M	﹤0.01%	3760
2024 Q1	$5.35M	Buy	793,170 +743,686	+1,503%	+$5.65M	﹤0.01%	1798
2023 Q4	$369K	Sell	49,484 -57,204	-54%	-$488K	﹤0.01%	4065
2023 Q3	$1.09M	Buy	+106,688	New	+$2.27M	﹤0.01%	2278

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's SLRN Position: Q2 2025 in Review

Barclays sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 82,871 shares — an estimated $205K sold.

Barclays first reported a position in SLRN in Q3 2023 and held it in 7 quarters. The position peaked at $5.35M in Q1 2024. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

Barclays reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
Barclays sold 82,871 ACELYRIN shares in Q2 2025, an estimated $205K.
Barclays first reported a position in ACELYRIN in Q3 2023 and held it in 7 quarters.
Barclays's ACELYRIN position peaked at $5.35M in Q1 2024.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.